Biofrontera

News Biofrontera

• European Commission authorizes EU-wide marketing and distribution of Biofrontera's Ameluz

  Biofrontera was informed by the European Commission that its product Ameluz® (in development called BF-200 ALA) was approved for distribution throughout the entire EU, Norway, Island and Liechtenstein. Already in October had the responsible "European Medicines Agency" recommended the approval that w more

• The EMA recommends approval of Biofrontera's BF-200 ALA

  The European Medicines Agency (EMA) issued a favourable opinion on Biofrontera's marketing approval application for its new medicinal product BF-200 ALA for the treatment of actinic keratosis. There was no recommendation for a restriction or temporal limitation of the approval. The product will be m more

• Positive review of the European Medicines Agency in the approval process of Biofrontera's BF-200 ALA

  Biofrontera has received a positive interim report of the responsible committee of the European Medicines Agency (EMA) in the ongoing centralized approval process of BF-200 ALA for the treatment of actinic keratosis.The "Committee for Medicinal Products for Human Use (CHMP)" provides applicants on d more

Market studies Biofrontera

• Chronic Urticaria or Hives Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Chronic Urticaria or Hives Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Chronic Urticaria Or Hives Therapeutics m more

• Biofrontera AG (B8F) - Financial and Strategic SWOT Analysis Review

  Biofrontera AG (Biofrontera) is a publicly held pharmaceutical company, engaged in the development of drugs for the treatment of dermatological and inflammatory diseases. The company's product pipeline includes, Belixos, a cream with herbal ingredients for the basic care of inflamed, itchy and flaky more

Websites Biofrontera